Complimentary Webinar: Cognoptix Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes in a Proof-of-Concept Clinical Trial

Data, published in Frontiers in Neurology, to be presented at the Alzheimer’s Association International Conference (AAIC) in Boston next month

--(BUSINESS WIRE)--“This simple eye test has the potential to transform the way Alzheimer’s disease is detected and managed.” Carl Sadowsky, MD, FAAN, Medical Director, Premiere Research Institute, West Palm Beach, Fla.

Complimentary Webinar
Wednesday, June 19, 2013
1:00-2:00 P.M. EDT

About Cognoptix

Cognoptix, a privately held medical technology company headquartered in Acton, Mass., is focused on developing and commercializing an in-office, drug/device diagnostic system as an aid in the early detection of Alzheimer’s Disease (AD). Its investors include Inventages Venture Capital, one of the world’s largest life sciences-, nutrition- and wellness-focused venture capital firms; and Launchpad Venture Group, a Boston-based angel investment firm that provides funding to early-stage companies.

NOTE: The SAPPHIRE II system is approved for investigational use only in the United States.